Quince Therapeutics publishes eDSP study data in pulmonary, IBD disorders

Quince Therapeutics Inc. (NASDAQ: QNCX) announced the publication of early-stage clinical study data for its Phase 3 lead asset eDSP in the scientific journal Frontiers in Drug Delivery. The publication summarizes results from eight clinical trials testing eDSP in patients with pulmonary and inflammatory bowel disorders.

eDSP consists of dexamethasone sodium phosphate encapsulated in a patient's own red blood cells. The early-stage studies examined patients aged five to 83 years with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Patients received infusions every two weeks or monthly with follow-ups ranging from one to 24 months.

According to the publication, eDSP resulted in improved lung function and reduced infections in cystic fibrosis patients and improved symptoms in chronic obstructive pulmonary disease patients with reduced corticosteroid doses. In inflammatory bowel disorders, eDSP enabled corticosteroid withdrawal in 60% to 78% of patients and achieved remission in pediatric and adult patients with Crohn's disease and ulcerative colitis.

The studies documented persistence of drug levels up to 28 days post-infusion, with mean doses not exceeding 10 mg per infusion. The company reported that adverse effects typically associated with corticosteroids were notably absent in these trials.

Quince is currently conducting its pivotal Phase 3 NEAT clinical trial of eDSP in patients with Ataxia-Telangiectasia, a rare neurodegenerative disorder. The company expects to report topline results from the NEAT study in the middle of the first quarter of 2026.

The information is based on a company press release statement.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49